Jill Quigley Biography and Net Worth

Jill M. Quigley serves as Chief Executive Officer of Genuiti Therapeutics.  Ms. Quigley also serves on the board of Chemomab Therapeutics Ltd., a publicly-traded biotechnology company. Previously, Ms. Quigley served as the Chief Operating Officer of Passage Bio, Inc., a publicly-traded biotechnology company, from November 2018 to December 2021. Prior to Passage Bio, she served as the Interim Chief Executive Officer and General Counsel of Nutrinia Ltd., from January 2016 to November 2018. Before joining Nutrinia, Ms. Quigley served as Senior Counsel of NPS Pharmaceuticals, Inc., a biotechnology company focused on developing treatments for rare diseases, which was acquired by Shire plc in March 2015. Ms. Quigley previously served as Corporate Counsel for Pharmasset, Inc., a pharmaceutical company acquired by Gilead Sciences in 2011. She also worked as an Associate with the law firm of Dechert LLP and later served as Assistant Corporate Counsel for Integra Life Sciences Holdings Corporation. Ms. Quigley holds a B.A. in Communications, Legal Institutions, Economics & Government (CLEG) from American University and a J.D. from Rutgers School of Law.